E-Nios spun out from the National Hellenic Research Foundation in 2013 to commercialize computational methods for identifying and prioritizing gene targets.
Internal benchmarks from the company show that the new technology, to be released next month, predicts variant pathogenicity with 98 percent accuracy.
The company was established earlier this year by the co-founders of reproductive genetics firm Recombine, which was sold to CooperSurgical in May.
BC Platforms will work with the personalized medicine firm to create a large-scale biobank of genetic and phenotypic data samples from Mexican individuals.
The Office of the National Coordinator for Health Information Technology's ability to test new standards and policies is hindered without $5 million Obama requested for FY2016.
In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.
Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.
Olympic athletes this summer will also undergo gene doping testing, according to Wired.
A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.